Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer

A prospective study was performed in patients with non-small cell lung cancer (NSCLC) to evaluate the prognostic importance of multiple molecular marker (p53, c-Ki-ras, c-erbB-2) testing. 103 patients with potentially curative resections (RO resection) for NSCLC in histopathological stages I–IIIA were included. SSCP analysis and DNA sequencing for p53 and c-Ki-ras genes were performed on paired tumour and normal lung tissue samples and immunohistochemistry (c-erbB-2) was done on frozen tissue sections with a specific anti-c-erbB-2 monoclonal antibody. 46/103 (44.6%) NSCLC showed p53 mutations and 17/103 (16.5%) c-Ki-ras mutations including 12/37 (32.4%) adenocarcinomas. Overexpression of c-erbB-2 (p185) was detected in 56/103 (54.4%) tumours. 24/103 (23.3%) NSCLC were negative for alterations in all 3 parameters (c-Ki-ras, p53 and p185) whereas 79/103 (76.7%) were positive for at least one of the 3 parameters. In a regression model including a multiple molecular marker parameter (negative for all 3 markers versus positive for at least one marker), histopathological stage (P< 0.00001), respectively the pT (P< 0.01) and pN (P< 0.00001) categories and the multiple molecular marker parameter (P< 0.01) were of significant prognostic importance. This study demonstrates that testing 3 molecular markers (c-Ki-ras, p53 and c-erbB-2) improves estimation of prognosis compared to single marker testing and appears to define low (82.6% ± 7.9% 5-year survival) and high risk (40.2% ± 5.5% 5-year survival) groups for treatment failure in potentially curative (RO) resected NSCLC. © 2000 Cancer Research Campaign

[1]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[2]  V. Rusch,et al.  p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. , 1994, Chest.

[3]  J. Roth,et al.  Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. , 1996, The Journal of thoracic and cardiovascular surgery.

[4]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[5]  S. Rodenhuis,et al.  C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. , 1994, The Journal of clinical investigation.

[6]  W. Sauerbrei,et al.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.

[7]  F. Ho,et al.  Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation. , 1994, Journal of clinical pathology.

[8]  G. Sozzi.  Molecular biology of lung cancer. , 2001, European journal of cancer.

[9]  S. Rodenhuis,et al.  Clinical significance of ras oncogene activation in human lung cancer. , 1992, Cancer research.

[10]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[11]  T. Sekiya,et al.  Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. , 1992, Cancer research.

[12]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[13]  Jack Nadler,et al.  Some Aspects of the Use of the Sequential Probability Ratio Test , 1958 .

[14]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[15]  G. van Kaick,et al.  New aspects in the staging of lung cancer. Prospective validation of the international union against cancer TNM classification , 1992, Cancer.

[16]  J. Roth,et al.  Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. , 1989, Cancer research.

[17]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[18]  A. Ariza,et al.  Molecular staging of non-small cell lung cancer according to K-ras genotypes. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[20]  C. Rose,et al.  Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. , 1996, British Journal of Cancer.

[21]  J. Minna,et al.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. , 1990, Oncogene.

[22]  C. Mountain.  Expanded possibilities for surgical treatment of lung cancer. Survival in stage IIIa disease. , 1990, Chest.

[23]  B. Johnson.  Biologic and molecular prognostic factors--impact on treatment of patients with non-small cell lung cancer. , 1995, Chest.

[24]  K. Sugimachi,et al.  ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.

[25]  K. Sugimachi,et al.  Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. , 1991, European journal of cancer.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[27]  E. Sauter,et al.  p53 and disease progression in patients with non-small cell lung cancer. , 1995, Surgical oncology.

[28]  J. Siegfried,et al.  Detection of K-ras mutations in lung carcinomas: relationship to prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  M. Humbert,et al.  Serum neopterin after lung transplantation. , 1993, Chest.

[30]  J. Minna.  The molecular biology of lung cancer pathogenesis. , 1993, Chest.

[31]  E. Holmes.  General principles of surgery quality control. , 1994, Chest.

[32]  F. Berthold,et al.  Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. , 1993, Cancer research.

[33]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[34]  J. Spurrier,et al.  Two-stage test of independence using Kendall's statistic. , 1980, Biometrics.

[35]  C. Mountain,et al.  A new international staging system for lung cancer. , 1987, Chest.

[36]  T. Mitsudomi,et al.  Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[37]  R. Tsuchiya,et al.  Prognosis and survival in resected lung carcinoma based on the new international staging system. , 1988, The Journal of thoracic and cardiovascular surgery.

[38]  M. Volm,et al.  Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. , 1992, Anticancer research.

[39]  F. Rosner.  Is living kidney donation still justifiable? , 1994, Chest.

[40]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[41]  S. Rodenhuis,et al.  Comparative analysis of p53 gene mutations and protein accumulation in human non‐small‐cell lung cancer , 1995, International journal of cancer.

[42]  R. Whyte,et al.  Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. , 1994, The Journal of thoracic and cardiovascular surgery.

[43]  M. Kraus,et al.  Increased erbB-2 gene copies and expression in multiple stages of breast cancer. , 1990, Cancer research.

[44]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[45]  M. Hung,et al.  Overexpression of the c‐erbB‐2/neu–encoded p185 protein in primary lung cancer , 1992, Molecular carcinogenesis.

[46]  D. Ryberg,et al.  p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. , 1994, Cancer Research.

[47]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.